[go: up one dir, main page]

WO2003016344A3 - Nouvelle utilisation - Google Patents

Nouvelle utilisation Download PDF

Info

Publication number
WO2003016344A3
WO2003016344A3 PCT/EP2002/009006 EP0209006W WO03016344A3 WO 2003016344 A3 WO2003016344 A3 WO 2003016344A3 EP 0209006 W EP0209006 W EP 0209006W WO 03016344 A3 WO03016344 A3 WO 03016344A3
Authority
WO
WIPO (PCT)
Prior art keywords
nsclc
lung cancer
carcinoma
lesions
small cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/009006
Other languages
English (en)
Other versions
WO2003016344A2 (fr
Inventor
Swann Romain Jean-Thoma Gaulis
Y De Bassols Carlota Vinals
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to AU2002331231A priority Critical patent/AU2002331231A1/en
Publication of WO2003016344A2 publication Critical patent/WO2003016344A2/fr
Publication of WO2003016344A3 publication Critical patent/WO2003016344A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/5752—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Utilisation des polypeptides et polynucléotides CASB933 en diagnostique, compositions et vaccins immunogènes utilisés dans la prévention et le traitement thérapeutique des cancers et notamment des lésions prénéoplasiques provoquées par le cancer du poumon, notamment le cancer pulmonaire à petites cellules (SCLC) ou un cancer pulmonaire 'non à petites cellules' (NSCLC) tel que l'éphithélioma spinocellulaire (épidermoïde), l'adénocarcinome (y compris l'adénocarcinome broncho-alvéolaire) et le carcinome à grandes cellules (non différentié), ou des carcinoïdes, ou des tumeurs bronchiales ou des mésothéliomes et plus particulièrement des lésions prénéoplasiques NSCLC à un stade précoce (stades de classification 0, ou IA, ou IB, ou IIA, ou IIB selon la classification des stades de Mountains).
PCT/EP2002/009006 2001-08-14 2002-08-12 Nouvelle utilisation Ceased WO2003016344A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002331231A AU2002331231A1 (en) 2001-08-14 2002-08-12 Use of lung carcinoma antigen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0119823A GB0119823D0 (en) 2001-08-14 2001-08-14 Novel compounds
GB0119823.3 2001-08-14

Publications (2)

Publication Number Publication Date
WO2003016344A2 WO2003016344A2 (fr) 2003-02-27
WO2003016344A3 true WO2003016344A3 (fr) 2003-11-20

Family

ID=9920387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/009006 Ceased WO2003016344A2 (fr) 2001-08-14 2002-08-12 Nouvelle utilisation

Country Status (3)

Country Link
AU (1) AU2002331231A1 (fr)
GB (1) GB0119823D0 (fr)
WO (1) WO2003016344A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0839908A2 (fr) * 1996-10-31 1998-05-06 Smithkline Beecham Corporation ELF3, un membre de la famille ETS
WO1998023782A2 (fr) * 1996-11-27 1998-06-04 The Regents Of The University Of California Nouveau gene lie a la famille ets, surexprime dans les cancers humains du sein et de l'epithelium
WO2000055350A1 (fr) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Sequences et polypeptides geniques associes au cancer chez l'homme
WO2000070092A1 (fr) * 1999-05-14 2000-11-23 Chiron Corporation Expression de proteines du domaine ets dans le cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0839908A2 (fr) * 1996-10-31 1998-05-06 Smithkline Beecham Corporation ELF3, un membre de la famille ETS
WO1998023782A2 (fr) * 1996-11-27 1998-06-04 The Regents Of The University Of California Nouveau gene lie a la famille ets, surexprime dans les cancers humains du sein et de l'epithelium
WO2000055350A1 (fr) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Sequences et polypeptides geniques associes au cancer chez l'homme
WO2000070092A1 (fr) * 1999-05-14 2000-11-23 Chiron Corporation Expression de proteines du domaine ets dans le cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHANG C-H ET AL: "ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis", ONCOGENE, vol. 14, no. 13, 1997, pages 1617 - 1622, XP000870110, ISSN: 0950-9232 *
TYMMS M J ET AL: "A novel epithelial-expressed ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer", ONCOGENE, vol. 15, no. 20, 13 November 1997 (1997-11-13), pages 2449 - 2462, XP000877469, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
GB0119823D0 (en) 2001-10-10
AU2002331231A1 (en) 2003-03-03
WO2003016344A2 (fr) 2003-02-27

Similar Documents

Publication Publication Date Title
WO2001062920A3 (fr) Compositions et methodes destinees au diagnostic et a la therapie du mesotheliome malin
EP1272636B8 (fr) Gene exprime de maniere differentielle dans le cancer du sein et de la vessie et polypeptides codes
WO2001092581A3 (fr) Compositions et methodes permettant le traitement et le diagnostic du cancer de l'ovaire
AU2003274823A1 (en) Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
AU4673099A (en) Use of bioadhesives and adjuvants for the mucosal delivery of antigens
WO2002092001A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer du poumon
MXPA06010469A (es) Proteina recombinante portadora de epitopos del virus de papiloma humano insertados en una proteina adenilato ciclasa o en un fragmento de ella y sus usos terapeuticos.
WO2007030668A3 (fr) Traitement systemique de cancers metastasiques et/ou systemiquement dissemines a l'aide de poxvirus exprimant le gm-csf
NZ524036A (en) Treatment and diagnosis of cancer
EP1409547A4 (fr) Procedes et compositions pharmaceutiques permettant la falsification immunitaire, particulierement utiles pour le traitement du cancer
AU2001251084A1 (en) Polynucleotides and polypeptides as well as methods for diagnosing and treating lung cancer
WO1999051263A3 (fr) Methodes et cellules modifiees pour le traitement du cancer
WO2003016344A3 (fr) Nouvelle utilisation
WO2005025497A3 (fr) Epitopes des lymphocytes t hpv cd8+
WO2003026494A3 (fr) Galectines-1 et -4 dans le developpement des tumeurs
WO2004099247A3 (fr) Gene synthetique codant pour l'antigene carcinoembryonnaire humain et son utilisation
WO2005000204A3 (fr) Traitement du cancer du pancreas
WO2003017944A3 (fr) Cytokines a ancrage gpi
AU2001249431A1 (en) Compositions and methods of diganosing, monitoring, staging, imaging and treating mammary gland cancer
WO2007137986A3 (fr) Méthode
DE60239690D1 (de) Sezernierte und zelloberflächengene, die in gutartigen und bösartigen kolorektaltumoren exprimiert werden
EP2193804A3 (fr) Toxine d'adénylate-cyclase récombinante de Bordetella induisant des réponses des lymphocytes T contre des antigènes tumoraux
WO2002078690A3 (fr) Agents anti-tumoraux taxoides et compositions pharmaceutiques basees sur ces derniers
SG148035A1 (en) Gene products differentially expressed in cancerous breast cells and their methods of use
WO2001094409A3 (fr) Traitement et diagnostic du cancer du pancreas et compositions a cet effet

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP